SIRT1 and neoplasm: Similar to SIRT1, SIRT6 has been reported to exhibit both oncogenic and tumor-suppressing effects, and both activators (e.g., 4H-chromen, fluvastatin, MDL-800, and MDL-811) and inhibitors (e.g., quercetin and quinazolinediones) of SIRT6 can become useful anticancer drugs depending on the molecular biological context and stage of the treated tumor [Table 4][145].